Biotech Values

[DewDiligence]

...VRTX won't merge because Joshua Berger is happy to be a main feature there.

Boger is only one vote on the BoD, and he isn’t directly involved in day-to-day operations anymore.

VRTX was my own vote in the survey of companies with >=$1B market cap; it was a close call between VRTX and AGN. As jq1234 noted, when suitors pay a large sum for a biotech acquisition, they invariably want proven products they can sell immediately or in the near future, and they typically justify the buyout premium by citing the cost synergies in SG&A.